Observes adults with lung cancer starting AstraZeneca cancer medicines
Follows adults with non-small cell lung cancer starting approved AstraZeneca medicines in routine care.
Plain-language title generated from the registry record
Registry title: UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Key facts
- Where
- Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel, L Rrach, Landshut, M Nnerstadt, Magdeburg, Neuss, Schorndorf, and Wiesbaden, GermanySee the 15 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer (NSCLC) who have just started an approved AstraZeneca (or alliance-developed) drug. The study only observes real-world care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- NSCLC proven by tissue or cell tests, at any stage (resectable, unresectable or metastatic)
- Earlier treatment
- Must have started an approved AstraZeneca (or alliance-developed) drug at enrollment or within the previous three weeks
Main reasons for not taking part
- Taking part in an interventional clinical trial for NSCLC (low-interventional studies where the intervention does not involve NSCLC treatment are allowed)
- Already enrolled in another module of this study
- Under safeguard of justice, curatorship or guardianship
Read by machine on 12 November 2026.
Where in Germany
- BerlinHospital not named in the registryNot yet recruiting
- DresdenHospital not named in the registryNot yet recruiting
- Frankfurt am MainHospital not named in the registryTaking people
- HalleHospital not named in the registryNot yet recruiting
- HamburgHospital not named in the registryNot yet recruiting
- HanoverHospital not named in the registryTaking people
- HeidelbergHospital not named in the registryNot yet recruiting
- KasselHospital not named in the registryNot yet recruiting
- L RrachHospital not named in the registryNot yet recruiting
- LandshutHospital not named in the registryNot yet recruiting
- M NnerstadtHospital not named in the registryNot yet recruiting
- MagdeburgHospital not named in the registryTaking people
- NeussHospital not named in the registryNot yet recruiting
- SchorndorfHospital not named in the registryNot yet recruiting
- WiesbadenHospital not named in the registryNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06726720
- Record updated
- 27 August 2026
- Original description
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries.Read full original descriptionShow less
A Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating AstraZeneca (or Alliance Developed) Drugs
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries.
Patients will be enrolled in the study if they have received (retrospective), receive (retrospective and prospective) or will receive (prospective) approved drugs developed by AZ or as part of an AZ alliance according to the eligibility criteria.
Treatment plan and decision are made independently by each treating physician prior to inclusion in this study.
Inclusion: Adult patients (≥ 18 years old); Patients with histologically or cytologically proven NSCLC; Patients initiated with approved drugs developed by AZ or as part of an AZ alliance at the time of the enrollment or within the previous three weeks; Informed patients who consent to participate in the study as per local regulations.
Exclusion: Patients participating in an interventional clinical trial for NSCLC*; with the exception on low-interventional studies (RIPH2) where the intervention does not involve the NSCLC treatment; Patients already enrolled in another module of the cohort in UMBREALUNG; Patients under safeguard of justice, curatorship or guardianship.